doi: 10.1161/01.RES.0000253139.82251.31
© 2006 American Heart Association, Inc.
Editorials |
ß-Catenin Nuclear Activation
Common Pathway Between Wnt and Growth Factor Signaling in Vascular Smooth Muscle Cell Proliferation?
From the Institut National de la Santé et de la Recherche Médicale (T.C., P.D., C.D.), Inserm U441, Pessac, France; Université Victor Segalen Bordeaux 2 (T.C., P.D., C.D.), Bordeaux, France; Department of Cardiology (T.C.), CHU Groupe Sud, Hôpital Haut Lévêque, Pessac, France.
Correspondence to Thierry Couffinhal, MD, PhD, Inserm U 441, Avenue du Haut-Lévêque, 33600 Pessac, France. E-mail thierry.couffinhal{at}bordeaux.inserm.fr
See related article, pages 1329–1337
Key Words: vascular cells • proliferation • ß-catenin • Wnt pathway
 |
Introduction |
|---|
 Top Introduction Central Role and Sharp...Wnt/ß-Catenin...References |
|---|
Understanding how smooth muscle cells transition from a steady state to a proliferative state will have an important impact on our understanding of vascular pathology. In the present issue of Circulation Research, Quasnichka et al take an indepth look at the role of the ß-catenin/T-cell factor (TCF) signaling pathway in vascular smooth muscle cell (VSMC) proliferation.1 Although ß-catenin is the central component in the Wnt canonical pathway, and is regarded as a hallmark of Wnt pathway activation, the present article and other recent reports elucidate new insights into activation of the ß-catenin pathway and indicates, that ß-catenin activation appears to be intricately orchestrated by both Wnt and growth factor networks.
|
Central Role and Sharp Regulation of ß-Catenin at the Molecular and Cellular Levels |
|---|
|
TopIntroductionCentral Role and Sharp...Wnt/ß-Catenin...References |
|---|
At the plasma membrane, it controls cell-cell adhesion through its binding with cadherin in adherence junctions and also mediates the link between cadherin and the actin cytoskeleton through the molecular switch
-catenin.2,3 In addition, ß-catenin acts as a transcriptional activator and regulates transcription of target genes responsible for cell proliferation and differentiation.4 Literature diverges on the interpretation of the interplay between these pathways. It is still unclear if these 2 processes act in concert or independently.5,6
The Wnt system is 1 of the well-known potent pathways, which activates nuclear ß-catenin. In the absence of Wnt signal, free cytoplasmic ß-catenin is phosphorylated by serine/threonine kinases, casein Kinase I (CKI) and GSK3ß in a large APC/axin scaffolding complex that targets ß-catenin for degradation. In the presence of Wnt signaling, this destruction complex is disrupted, and dissociation of GSK3ß prevents phosphorylation of ß-catenin. The increase stability of ß-catenin following Wnt activation leads to its translocation in the nucleus and induces transcriptional activation of target genes by ß-catenin interaction with TCF/LEF (lymphoid enhancer factor) DNA-binding proteins (Figure).
|
Regulation of ß-catenin activity is thought to occur mainly at the level of protein degradation but there is considerable evidence now that its activity depends on its subcellular localization, which is regulated by interaction with distinct partners.7 LEF/TCF8,9 and a complex of B-cell lymphoma 9 (BCL9)10,11 can recruit ß-catenin in the nucleus. Conversely, axin as APC complex promotes a nuclear-cytoplasmic shuttling of ß-catenin and regulates ß-catenin subcellular distribution.12 Gottardi et al proposed that under Wnt stimuli, a monomeric form of ß-catenin interacts preferentially with LEF/TCF transcription factor and not with cadherin, while ß-catenin--catenin dimer would be involved in adhesion complex.13
The function of ß-catenin is regulated sharply through tyrosine phosphorylation on 2 tyrosine residues 142 and 654 and results in the disruption of cadherin binding. Tyrosine 654 phosphorylation, by c-src for example, is essential for ß-catenin/E-cadherin complex stabilization. Interestingly, phosphorylation of ß-catenin at tyrosine 142 by distinct tyrosine kinases, such as Met, Fer, or Fyn kinase,14 diminishes ß-catenin affinity to -catenin in the E-cadherin complex but enhances its binding to the transcriptional coactivator BCL9–2.15 This leads, in conjunction with LEF/TCF, to increased transcriptional activities.
Growth Factor Induced ß-Catenin/TCF Pathway for Vascular Cell Proliferation
In an elegant series of experiments, Quasnichka et al demonstrate how growth factors (PDGF and bFGF), via the activation of ß-catenin/TCF signaling, modulate VSMC proliferation through cyclin D1 and p21 modulation.1 The authors have previously shown that VSMC growth factor stimulation leads to N-cadherin shedding, in part by metalloproteinase dependent proteolysis. This is accompanied by translocation of ß-catenin to the nucleus, where it associates with the transcription factor LEF-1, playing a direct role in modulating VSMC proliferation.16
The authors used a set of original reagents, which warrant description, as they are essential to understanding the study results. To block ß-catenin/TCF signaling, they used adenovirus approaches and a cationic lipid delivery of anti-ß-catenin antibody. Adenovirus RAd dn-TCF-4 was used to express dominant negative TCF-4. Adenovirus RAd ICAT expressed the ß-catenin-interacting protein, ICAT, which inhibits the interaction of ß-catenin with TCF, preventing formation of the transactivator complex and thereby negatively regulating ß-catenin-TCF–mediated transcription. RAd FL-N-cadherin indirectly inhibited ß-catenin/TCF signaling by increasing cell-cell junctions and thereby lowering free cytosolic ß-catenin by binding it to the cell membrane.
It has been previously shown that cyclin D1 expression is increased and p21 repressed by ß-catenin/TCF signaling. Quasnichka et al further demonstrate that PDGF and bFGF activate cyclin D1 promoter, cyclin D1 messenger RNA (mRNA) and protein expression in VSMC and that this activation is partially repressed by inhibiting the ß-catenin/TCF pathway or lowering free cytosolic ß-catenin. In parallel, the authors report that growth factors do not activate p21 promoter activity or modulate p21 mRNA or protein expression in VSMC. However, inhibiting the ß-catenin/TCF pathway lead to an activation of p21 promoter and to an increase in mRNA and protein expression. These results were further corroborated in experiments using human saphenous vein segments.
The authors validate their results in cyclin D1 deficient (CD1–/–) and p21 deficient (p21–/–) mouse aortic VSMC. They demonstrate that growth factors induce proliferation of CD1–/– and p21–/– VSMC. In contrast, in wild type VSMC, blocking ß–catenin/TCF signaling did not alter this response, confirming that cyclin D1 and p21 are necessary to exert the proliferative effect of ß-catenin/TCF signaling induced by growth factors (Figure).
|
Wnt/ß-Catenin Signaling in the Vasculature |
|---|
|
TopIntroductionCentral Role and Sharp...Wnt/ß-Catenin...References |
|---|
Although growth factors are known to coordinate dynamic changes in cell adhesion and proliferation, ongoing studies have now provided strong evidence that the canonical Wnt–ß-catenin pathway is of particular importance in adult vascular cell proliferation.17–21
Genetic data from mouse studies have emphasized the critical role of some Wnt proteins or their receptors Frizzled (fz) in vascular development. For example, inactivation of Frizzled 5 and Frizzled 4 induced defects in vessels in the yolk sac and placenta22 and in retinal vascular network,23 respectively. Recent analysis of Wnt pathway components in blood vessels revealed that the canonical Wnt–ß-catenin pathway is present in vascular cells activated by a vascular lesion or an ischemia event, and this pathway appears to regulate vascular smooth muscle proliferation and apoptosis.24 In vivo, ß-catenin stabilization correlates with VSMC proliferation in a rat carotid artery balloon-injury model.20 The same group demonstrated the role for a Wnt coreceptor, the lipoprotein receptor-related protein (LRP-6), in the regulation of VSMC proliferation and survival through the Wnt signaling cascade.19 sFRP-1, a Wnt pathway modulator, was shown to delay the G1 phase and entry into S-phase of EC and VSMC and also modulated the levels of the cyclin D1, E and the associated cyclin-dependent kinases cdk2 and cdk4.18 This effect was in part ß-catenin dependent. Others have observed that, after myocardial injury, ß-catenin is translocated from the plasma membrane to the cytoplasm of endothelial cells during the phase of neovascularization of the infarct area21 and that sFRP-1 overexpression decreased ß-catenin cytosolic accumulation in vascular cells compared with that in control mouse hearts.25
Thus, the work of Quasnichka et al elicits important questions for the vascular field. How do Wnt and growth factors signal through ß-catenin nuclear activation? Do they regulate through a parallel or common pathway? By which molecular mechanism is the dual function of ß-catenin in cell adhesion and gene transcription regulated? A recent clue to another route, parallel to the Wnt pathway, for ß-catenin translocation has begun to emerge. Yang et al propose in a model of epithelial-mesenchymal transition, in which PDGF activation induces p68 RNA Helicase phosphorylation, displacing the complex axin-GSK3ß from ß-catenin, favoring its translocation in the nucleus,6 independently of the Wnt pathway (Figure).
The tight regulation of the balance between a quiescent VSMC firmly adherent to the extra cellular matrix or to a neighboring cell and a VSMC that dismantles its junctions, proliferates and migrates is a key point of many vascular diseases, such as atherosclerosis, vascular rejection or restenosis after angioplasty but also neovessel muscularization and maturation in ischemic or in tumor diseases. ß-catenin is at the crossroad of growth factor and morphogen paths that sharply control VSMC proliferation. Understanding the interactions between these pathways is an exciting challenge.
|
Acknowledgments |
|---|
Sources of Funding
T.C., P.D., and C.D. work was supported by the Inserm, Université de Bordeaux 2, IFR4-FR21, Fondation de France, European Vascular Genomic Network, Agence Nationale de la Recherche, Groupe de Réflexion sur la Recherche Cardiovasculaire, and the Foundation pour la Recherche Médicale.
Disclosures
None.
|
Footnotes |
|---|
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
|
References |
|---|
|
TopIntroductionCentral Role and Sharp...Wnt/ß-Catenin...References |
|---|
1. Quasnichka H, Slater SC, Beeching CA, Boehm B, Sala-Newby GB, George SJ. Regulation of Smooth Muscle Cell Proliferation by [beta]-catenin/TCF Signaling Involves Modulation of Cyclin D1 and p21 Expression. Circ Res. 2006; 99: 1329–1337.
2. Drees F, Pokutta S, Yamada S, Nelson WJ, Weis WI. Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell. 2005; 123: 903–915.[CrossRef][Medline] [Order article via Infotrieve]
3. Yamada S, Pokutta S, Drees F, Weis WI, and Nelson WJ. Deconstructing the cadherin-catenin-actin complex. Cell. 2005; 123: 889–901.[CrossRef][Medline] [Order article via Infotrieve]
4. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004; 303: 1483–1487.
5. Park JI, Kim SW, Lyons JP, Ji H, Nguyen TT, Cho K, Barton MC, Deroo T, Vleminckx K, Moon RT, McCrea PD. Kaiso/p120-catenin and TCF/beta-catenin complexes coordinately regulate canonical Wnt gene targets. Dev Cell. 2005; 8: 843–854.[CrossRef][Medline] [Order article via Infotrieve]
6. Yang L, Lin C, Liu ZR. P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell. 2006; 127: 139–155.[CrossRef][Medline] [Order article via Infotrieve]
7. Krieghoff E, Behrens J, Mayr B. Nucleo-cytoplasmic distribution of beta-catenin is regulated by retention. J Cell Sci. 2006; 119: 1453–1463.
8. Behrens J, von Kries JP, Külh M, Bruhn L, Wedlich D, Grosscheld R, Birchmeier W. Functional interaction of ß-catenin with the transcription factor LEF-1. Nature. 1996; 382: 638–642.[CrossRef][Medline] [Order article via Infotrieve]
9. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999; 398: 422–426.[CrossRef][Medline] [Order article via Infotrieve]
10. Townsley FM, Cliffe A, Bienz M. Pygopus and Legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function. Nat Cell Biol. 2004; 6: 626–633.[CrossRef][Medline] [Order article via Infotrieve]
11. Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S, Murone M, Zullig S, Basler K. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell. 2002; 109: 47–60.[CrossRef][Medline] [Order article via Infotrieve]
12. Cong F, Varmus H. Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of beta-catenin. Proc Natl Acad Sci U S A. 2004; 101: 2882–2887.
13. Gottardi CJ, Gumbiner BM. Distinct molecular forms of beta-catenin are targeted to adhesive or transcriptional complexes. J Cell Biol. 2004; 167: 339–349.
14. Piedra J, Miravet S, Castano J, Palmer HG, Heisterkamp N, Garcia de Herreros A, Dunach M. p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction. Mol Cell Biol. 2003; 23: 2287–2297.
15. Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hammerschmidt M, Birchmeier W. Essential role of BCL9–2 in the switch between beta-catenin’s adhesive and transcriptional functions. Genes Dev. 2004; 18: 2225–2230.
16. Uglow EB, Slater S, Sala-Newby GB, Aguilera-Garcia CM, Angelini GD, Newby AC, George SJ. Dismantling of cadherin-mediated cell-cell contacts modulates smooth muscle cell proliferation. Circ Res. 2003; 92: 1314–1321.
17. Dufourcq P, Couffinhal T, Ezan J, Barandon L, Moreau M, Daret D, Duplàa C. FrzA, a secreted Frizzled Related Protein, induced angiogenic response. Circulation. 2002; 106: 3097–3103.
18. Ezan J, Leroux L, Barandon L, Dufourcq P, Jaspard B, Moreau C, Allieres C, Daret D, Couffinhal T, Duplaa C. FrzA/sFRP-1, a secreted antagonist of the Wnt-Frizzled pathway, controls vascular cell proliferation in vitro and in vivo. Cardiovasc Res. 2004; 63: 731–738.
19. Wang X, Adhikari N, Li Q, Hall JL. LDL receptor-related protein LRP6 regulates proliferation and survival through the Wnt cascade in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2004; 287: H2376–2383.
20. Wang X, Xiao Y, Mou Y, Zhao Y, Blankesteijn WM, Hall JL. A role for the beta-catenin/T-cell factor signaling cascade in vascular remodeling. Circ Res. 2002; 90: 340–347.
21. Blankesteijn WM, van Gijn ME, Essers-Janssen YP, Daemen MJ, Smits JF. Beta-catenin, an inducer of uncontrolled cell proliferation and migration in malignancies, is localized in the cytoplasm of vascular endothelium during neovascularization after myocardial infarction. Am. J. Pathol. 2000; 157: 877–883.
22. Ishikawa T, Tamai Y, Zorn AM, Yoshida H, Seldin MF, Nishikawa S, Taketo MM. Mouse Wnt receptor gene Fzd5 is essential for yolk sac and placental angiogenesis. Development. 2001; 128: 25–33.[Abstract]
23. Xu Q, Wang Y, Dabdoub A, Smallwood PM, Williams J, Woods C, Kelley MW, Jiang L, Tasman W, Zhang K, Nathans J. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell. 2004; 116: 883–895.[CrossRef][Medline] [Order article via Infotrieve]
24. Goodwin AM, D’Amore PA. Wnt signaling in the vasculature. Angiogenesis. 2002; 5: 1–9.[Medline] [Order article via Infotrieve]
25. Barandon L, Couffinhal T, Ezan J, Dufourcq P, Costet P, Alzieu P, Leroux L, Moreau C, Dare D, Duplaa C. Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation. 2003; 108: 2282–2289.
This article has been cited by other articles:
 |
|
 |
|
  N. Comes and T. Borras Individual molecular response to elevated intraocular pressure in perfused postmortem human eyes Physiol Genomics, July 9, 2009; 38(2): 205 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bedel, A. Negre-Salvayre, S. Heeneman, M.-H. Grazide, J.-C. Thiers, R. Salvayre, and F. Maupas-Schwalm E-Cadherin/{beta}-Catenin/T-Cell Factor Pathway Is Involved in Smooth Muscle Cell Proliferation Elicited by Oxidized Low-Density Lipoprotein Circ. Res., September 26, 2008; 103(7): 694 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M.L. Beckers, J. J. Garcia-Vallejo, V. W.M. van Hinsbergh, and G. P. van Nieuw Amerongen Nuclear targeting of {beta}-catenin and p120ctn during thrombin-induced endothelial barrier dysfunction Cardiovasc Res, September 1, 2008; 79(4): 679 - 688. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||